
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of ...
SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …